Suppr超能文献

蛋白质组学研究 HSP90 及其对医学研究的启示。

Proteomic interrogation of HSP90 and insights for medical research.

机构信息

a Center for Integrative Genomics , University of Lausanne , Lausanne , Switzerland.

b Chemical Biology Program , Memorial Sloan Kettering Cancer Center , New York , NY , USA.

出版信息

Expert Rev Proteomics. 2017 Dec;14(12):1105-1117. doi: 10.1080/14789450.2017.1389649. Epub 2017 Oct 16.

Abstract

Heat shock protein 90 (HSP90) regulates protein homeostasis in eukaryotes. As a 'professional interactor', HSP90 binds to and chaperones many proteins and has both housekeeping and disease-related functions but its regulation remains in part elusive. HSP90 complexes are a target for therapy, notably against cancer, and several inhibitors are currently in clinical trials. Proteomic studies have revealed the vast interaction network of HSP90 and, in doing so, the extent of cellular processes the chaperone takes part in, especially in yeast and human cells. Furthermore, small-molecule inhibitors were used to probe the global impact of its inhibition on the proteome. Areas covered: We review here recent HSP90-related interactomics and total proteome studies and their relevance for research on cancer, neurodegenerative and pathogen diseases. Expert commentary: Proteomics experiments are our best chance to identify the context-dependent global proteome of HSP90 and thus uncover and understand its disease-specific biology. However, understanding the complexity of HSP90 will require multiple complementary, quantitative approaches and novel bioinformatics to translate interactions into ordered functional networks and pathways. Developing therapies will necessitate more knowledge on HSP90 complexes and networks with disease relevance and on total proteome changes induced by their perturbation. Most work has been done in cancer, thus a lot remains to be done in the context of other diseases.

摘要

热休克蛋白 90(HSP90)调节真核生物的蛋白质动态平衡。作为一种“专业的相互作用蛋白”,HSP90 与许多蛋白质结合并为其提供伴侣,具有管家和与疾病相关的功能,但它的调节仍然部分难以捉摸。HSP90 复合物是治疗的靶点,特别是针对癌症,目前有几种抑制剂正在临床试验中。蛋白质组学研究揭示了 HSP90 的广泛相互作用网络,从而揭示了伴侣参与的细胞过程的程度,尤其是在酵母和人类细胞中。此外,小分子抑制剂被用于探测其对蛋白质组的全面抑制作用。涵盖领域:在这里,我们回顾了最近与 HSP90 相关的相互作用组学和总蛋白质组学研究,以及它们对癌症、神经退行性和病原体疾病研究的相关性。专家评论:蛋白质组学实验是我们识别 HSP90 上下文相关的全局蛋白质组的最佳机会,从而发现和理解其特定疾病的生物学。然而,理解 HSP90 的复杂性将需要多种互补的、定量的方法和新的生物信息学,将相互作用转化为有序的功能网络和途径。开发治疗方法需要更多关于 HSP90 复合物和与疾病相关的网络以及其扰动引起的总蛋白质组变化的知识。大多数工作都集中在癌症方面,因此在其他疾病方面还有很多工作要做。

相似文献

1
Proteomic interrogation of HSP90 and insights for medical research.
Expert Rev Proteomics. 2017 Dec;14(12):1105-1117. doi: 10.1080/14789450.2017.1389649. Epub 2017 Oct 16.
3
Approaches for defining the Hsp90-dependent proteome.
Biochim Biophys Acta. 2012 Mar;1823(3):656-67. doi: 10.1016/j.bbamcr.2011.08.013. Epub 2011 Aug 27.
4
Dynamic impacts of the inhibition of the molecular chaperone Hsp90 on the T-cell proteome have implications for anti-cancer therapy.
PLoS One. 2013 Nov 27;8(11):e80425. doi: 10.1371/journal.pone.0080425. eCollection 2013.
5
Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Curr Med Chem. 2008;15(26):2702-17. doi: 10.2174/092986708786242895.
6
Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.
Curr Top Med Chem. 2009;9(15):1447-61. doi: 10.2174/156802609789895683.
8
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.
Nat Chem Biol. 2011 Sep 25;7(11):818-26. doi: 10.1038/nchembio.670.
9
Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Adv Cancer Res. 2016;129:31-50. doi: 10.1016/bs.acr.2015.09.002. Epub 2015 Oct 23.
10
The expanding proteome of the molecular chaperone HSP90.
Cell Cycle. 2012 Apr 1;11(7):1301-8. doi: 10.4161/cc.19722.

引用本文的文献

2
The roles of molecular chaperones in regulating cell metabolism.
FEBS Lett. 2023 Jul;597(13):1681-1701. doi: 10.1002/1873-3468.14682. Epub 2023 Jun 16.
5
Proteomics and its applications in breast cancer.
Am J Cancer Res. 2021 Sep 15;11(9):4006-4049. eCollection 2021.
6
Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma.
Int J Mol Sci. 2021 Mar 3;22(5):2538. doi: 10.3390/ijms22052538.
7
First Virtual International Congress on Cellular and Organismal Stress Responses, November 5-6, 2020.
Cell Stress Chaperones. 2021 Mar;26(2):289-295. doi: 10.1007/s12192-021-01192-7. Epub 2021 Feb 9.
9
Chaperome Networks - Redundancy and Implications for Cancer Treatment.
Adv Exp Med Biol. 2020;1243:87-99. doi: 10.1007/978-3-030-40204-4_6.

本文引用的文献

1
A chemical compound inhibiting the Aha1-Hsp90 chaperone complex.
J Biol Chem. 2017 Oct 13;292(41):17073-17083. doi: 10.1074/jbc.M117.797829. Epub 2017 Aug 28.
2
Hsp90 activator Aha1 drives production of pathological tau aggregates.
Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9707-9712. doi: 10.1073/pnas.1707039114. Epub 2017 Aug 21.
3
Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
Mol Cancer Ther. 2017 Sep;16(9):1779-1790. doi: 10.1158/1535-7163.MCT-16-0848. Epub 2017 Jun 15.
4
Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
Eur J Med Chem. 2017 Aug 18;136:63-73. doi: 10.1016/j.ejmech.2017.04.074. Epub 2017 Apr 30.
5
The HSP90 chaperone machinery.
Nat Rev Mol Cell Biol. 2017 Jun;18(6):345-360. doi: 10.1038/nrm.2017.20. Epub 2017 Apr 21.
6
Regulatory Mechanisms of Hsp90.
Biochem Mol Biol J. 2017 Jan 30;3(1):2. doi: 10.21767/2471-8084.100030.
7
How Selective are Hsp90 Inhibitors for Cancer Cells over Normal Cells?
ChemMedChem. 2017 Mar 7;12(5):353-357. doi: 10.1002/cmdc.201600595. Epub 2017 Feb 27.
9
Novobiocin Analogs as Potential Anticancer Agents.
Mini Rev Med Chem. 2017;17(9):728-733. doi: 10.2174/1389557516666161223155525.
10
Heat Shock Proteins and Cancer.
Trends Pharmacol Sci. 2017 Mar;38(3):226-256. doi: 10.1016/j.tips.2016.11.009. Epub 2016 Dec 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验